Against this background, we report early preclinical findings with a first-in-class humanized anti-FSH monoclonal antibody, IGX12, that potentiates FSH activity and stimulates spermatogenesis in azoospermic animal models, an initial step in developing a novel approach to the management of male infertility. This evidence concerns the gene BRD2 and male infertility.